Shares of Trimeris (Nasdaq:TRMS) have taken a tremendous swing upward. The stock is trading at $2.41 as of 3:40 p.m. ET, 23.6% above Monday's closing price of $1.95. Volume is at 1.2 million, 11 times the daily average of 106,500.
NEW YORK ( TheStreet) -- Shares of Trimeris (Nasdaq: TRMS) have taken a tremendous swing upward. The stock is trading at $2.41 as of 3:40 p.m. ET, 23.6% above Monday's closing price of $1.95. Volume is at 1.2 million, 11 times the daily average of 106,500. Trimeris has a market cap of $43.2 million and is part of the health care sector and drugs industry. Shares are down 20.7% year to date as of the close of trading on Monday. Trimeris, Inc., a biopharmaceutical company, engages in the development of a class of antiviral drug treatments. Its fusion inhibitors prevent viral fusion, a complex process by which viruses attach to, penetrate, and infect host cells. The company has a P/E ratio of 2.4, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Trimeris as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, poor profit margins and a generally disappointing performance in the stock itself. You can view the full Trimeris Ratings Report. See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center. Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.